Published in Nature on August 03, 1973
McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-fms). J Virol (1982) 2.76
Feline leukemia virus: biochemical and immunological characterization of gag gene-coded structural proteins. J Virol (1977) 2.26
Nucleotide sequence of the envelope gene of Gardner-Arnstein feline leukemia virus B reveals unique sequence homologies with a murine mink cell focus-forming virus. J Virol (1983) 2.24
Properties of feline leukemia virus. I. Chromatographic separation and analysis of the polypeptides. J Virol (1974) 1.51
Sequence organization of feline leukemia virus DNA in infected cells. Nucleic Acids Res (1980) 1.42
Radiation leukemia in C57BL/6 mice. II. Lack of ecotropic virus expression in the majority of lymphomas. J Exp Med (1976) 1.32
Feline oncornavirus-associated cell-membrane antigen (FOCMA): distinction between FOCMA and the major virion glycoprotein. Proc Natl Acad Sci U S A (1977) 1.30
Method to map antigenic determinants recognized by monoclonal antibodies: localization of a determinant of virus neutralization on the feline leukemia virus envelope protein gp70. Proc Natl Acad Sci U S A (1984) 1.28
Relationship between RNA-directed DNA polymerase (reverse transcriptase) from human acute leukemic blood cells and primate type-C viruses. Proc Natl Acad Sci U S A (1974) 1.27
Nucleotide sequences of the envelope genes of two isolates of feline leukemia virus subgroup B. J Virol (1984) 1.26
Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein. J Virol (1985) 1.26
Serological definition of the lentivirus group of retroviruses. J Virol (1979) 1.20
The Parodi-Irgens feline sarcoma virus and simian sarcoma virus have homologous oncogenes, but in different contexts of the viral genomes. J Virol (1983) 1.05
Localization of neutralizing regions of the envelope gene of feline leukemia virus by using anti-synthetic peptide antibodies. J Virol (1987) 1.04
Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol (2009) 0.99
Naturally occurring persistent feline oncornavirus infections in the absence of disease. Infect Immun (1975) 0.99
Molecular analysis of several classes of endogenous feline leukemia virus elements. J Virol (1985) 0.97
Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA). J Virol (1998) 0.97
Feline preleukemia: an animal model of human disease. Yale J Biol Med (1979) 0.95
Endogenous RD-114 virus genome expression in malignant tissues of domestic cats. J Virol (1977) 0.95
Genetic characterization of feline leukemia virus from Florida panthers. Emerg Infect Dis (2008) 0.92
Differential pathogenicity of two feline leukemia virus subgroup A molecular clones, pFRA and pF6A. J Virol (2000) 0.90
B-cell and T-cell lymphomas and other associated diseases induced by an infectious DNA viroid-like agent in hamsters (Mesocricetus auratus). Am J Pathol (1983) 0.89
Update on Canine and Feline Blood Donor Screening for Blood-Borne Pathogens. J Vet Intern Med (2016) 0.88
Cat leukemia and the cluster controversy. Can Med Assoc J (1978) 0.88
Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated. Infect Immun (1977) 0.88
Evolution and modes of transmission of RNA tumor viruses. Parke-Davis Award lecture. Am J Pathol (1975) 0.87
Detection of feline leukemia virus infection in saliva. J Clin Microbiol (1987) 0.86
Animal model: feline acute lymphoblastic leukemia and aplastic anemia. Am J Pathol (1977) 0.86
Epizootiology and management of feline leukemia virus in the Florida puma. J Wildl Dis (2008) 0.85
Development and application of a quantitative real-time PCR assay to detect feline leukemia virus RNA. Vet Immunol Immunopathol (2008) 0.84
Prevalence and risk factors of feline leukaemia virus and feline immunodeficiency virus in peninsular Malaysia. BMC Vet Res (2012) 0.83
Neoplasms in domestic animals: a review of experimental and spontaneous carcinogenesis. Yale J Biol Med (1981) 0.82
Comparative analysis of the genomes of feline leukemia viruses. J Virol (1980) 0.81
Interspecies determinants of Friend leukemia virus antigens involved in cytolysis of virus-pfoducing cells. J Virol (1977) 0.81
Saliva as a source of feline leukemia virus antigen for diagnosis of disease. J Clin Microbiol (1987) 0.81
Feline leukemia virus: survival under home and laboratory conditions. J Clin Microbiol (1979) 0.80
Humoral immune response of asymptomatic cats naturally infected with feline leukemia virus. J Virol (1986) 0.80
Leukaemia 'firsts' in cancer research and treatment. Nat Rev Cancer (2016) 0.79
Retroviral DNA-the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats. Retrovirology (2015) 0.79
Identification of novel subgroup A variants with enhanced receptor binding and replicative capacity in primary isolates of anaemogenic strains of feline leukaemia virus. Retrovirology (2012) 0.78
RNA-tumour-virus genes and transforming genes: patterns of transmission. Br J Cancer (1978) 0.78
Long-term infection and vertical transmission of a gammaretrovirus in a foreign host species. PLoS One (2012) 0.78
Uterine adenocarcinoma with feline leukemia virus infection. Lab Anim Res (2011) 0.78
Differential inhibitory effects of cyanovirin-N, griffithsin, and scytovirin on entry mediated by envelopes of gammaretroviruses and deltaretroviruses. J Virol (2013) 0.77
Feline models of viral pathogenesis: opportunity knocks. Vet J (2010) 0.75
[Immunity against cancer. Use of spontaneous tumors of domestic animals as models for research: 1]. Bull World Health Organ (1974) 0.75
The relation of immune response to pathogenesis, vaccination and epidemiology in virus induced leukaemia. Br J Cancer Suppl (1975) 0.75
Endogenous RD-114 virus of cats: absence of antibodies to RD-114 envelope antigens in cats naturally exposed to feline leukemia virus. Infect Immun (1979) 0.75
Immunity to cancer. Naturally occurring tumours in domestic animals as models for research. 1. Bull World Health Organ (1973) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
Tumor necrosis factor (TNF). Science (1985) 8.80
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 6.38
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Male circumcision: an acceptable strategy for HIV prevention in Botswana. Sex Transm Infect (2003) 5.26
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature (1986) 4.90
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med (2000) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93
Feline oncornavirus-associated cell membrane antigen: evidence for an immunologically crossreactive feline sarcoma virus-coded protein. Proc Natl Acad Sci U S A (1977) 2.93
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. Proc Natl Acad Sci U S A (1970) 2.77
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 2.74
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet (1977) 2.69
Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67
Use of hybrid antibody with anti-gamma-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med (1968) 2.62
Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol (1990) 2.60
Detection of antibody to autologous human leukemia cells by immune adherence assays. Proc Natl Acad Sci U S A (1977) 2.59
Occurrence of natural antibody to the G (gross) leukemia antigen in mice. Cancer Res (1966) 2.57
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Thymus cells of radiation-chimeras: TL phenotype, sensitivity to guinea-pig serum, and origin from donor cells. Nature (1965) 2.54
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci U S A (1999) 2.53
Leukemia-associated transplantation antigens related to murine leukemia virus. The X.1 system: immune response controlled by a locus linked to H-2. J Exp Med (1973) 2.52
The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol (1992) 2.51
Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science (1983) 2.48
Serologically demonstrable alloantigens of mouse epidermal cells. J Exp Med (1972) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet (1986) 2.48
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A (1994) 2.44
Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1976) 2.42
Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol (2003) 2.40
A seronegative case of HIV-1 subtype C infection in Botswana. Clin Infect Dis (2007) 2.39
A naturally immunogenic virion-associated protein specific for HIV-2 and SIV. Nature (1988) 2.33
Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science (1986) 2.33
A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care (1991) 2.30
Group-specific viral antigens in the milk and tissues of mice naturally infected with mammary tumor virus or Gross leukemia virus. Virology (1968) 2.26